试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-08
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
编号:NCT05394350登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:MK-1088、Pembrolizumab
登记的停止原因(原文):Business Reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-08
Investigating Orthobiologics After PRP and Photobiomodulation for Knee Osteoarthritis
编号:NCT06122116登记状态:提前终止企业 / 申办者:Musculoskeletal Injury Rehabilitation Research for Operational Readiness
药物 / 成分:Physical Therapy、Platelet-Rich Plasma Injection、Photobiomodulation Therapy
登记的停止原因(原文):The Institutional Review Board terminated the protocol on 10 October 2024.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-07
A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies
编号:NCT01705483登记状态:提前终止企业 / 申办者:Astellas Pharma Global Development, Inc.
药物 / 成分:ASP9853、Docetaxel、Paclitaxel
登记的停止原因(原文):Based on the results of the Phase 1 data, the company decided not to pursue the development of this drug at this time.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-07
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
编号:NCT02646800登记状态:提前终止企业 / 申办者:Astellas Pharma China, Inc.
药物 / 成分:Micafungin
登记的停止原因(原文):Due to administrative reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-07
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
编号:NCT03833427登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:Selumetinib、Pembrolizumab
登记的停止原因(原文):Business Reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-07
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
编号:NCT04220775登记状态:提前终止企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Bintrafusp Alfa、Quality-of-Life Assessment、Questionnaire Administration、Stereotactic Body Radiation Therapy
登记的停止原因(原文):The sponsor decided to no longer develop the drug and stop support of studies using the drug.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-07
Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin
编号:NCT04994431登记状态:提前终止企业 / 申办者:University of Massachusetts, Worcester
药物 / 成分:Tamsulosin Hydrochloride
登记的停止原因(原文):inability to recruit
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-07
Vitamin C as add-on Therapy in Patients With Acute Herpes Zoster
编号:NCT05561257登记状态:提前终止企业 / 申办者:Pascoe Pharmazeutische Praeparate GmbH
药物 / 成分:Vitamin C
登记的停止原因(原文):the necessary recruitment was no longer ensured and fundamental changes in the medical care of herpes zoster, which prevented the original research objectives and the feasibility of the study in the planned scope from being achieved
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-06
The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II
编号:NCT02281838登记状态:提前终止企业 / 申办者:University of Alberta
药物 / 成分:labetalol/hydralazine/enalapril
登记的停止原因(原文):Slow enrolment after publication of the Interact III study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
编号:NCT03512756登记状态:提前终止企业 / 申办者:Tyme, Inc
药物 / 成分:SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)、Capecitabine, Gemcitabine, and 5-FU
登记的停止原因(原文):Sponsor's decision
查看官方原始记录 ↗